Selectivity of the photosensitiser Tookad® for photodynamic therapy evaluated in the Syrian golden hamster cheek pouch tumour model by Borle, F et al.
Selectivity of the photosensitiser Tookad
s for photodynamic
therapy evaluated in the Syrian golden hamster cheek pouch
tumour model
F Borle
1, A Radu
2, C Fontolliet
3, H van den Bergh
1, P Monnier
2 and G Wagnie `res*,1
1Institute of Environmental Engineering, Swiss Federal Institute of Technology (EPFL), CH-1015 Lausanne, Switzerland;
2Department of Otolaryngology,
Head and Neck Surgery, CHUV Hospital, CH-1011 Lausanne, Switzerland;
3Institute of Pathology, University of Lausanne, CH-1011 Lausanne,
Switzerland
The response to photodynamic therapy (PDT) with the photosensitiser (PS) Tookad
s was measured in the Syrian hamster cheek
pouch model on normal mucosae and chemically induced squamous cell carcinoma. This PS is a palladium-bacteriopheophorbide
presenting absorption peaks at 538 and 762nm. The light dose, drug dose and drug injection-light irradiation times (DLI), ranging
between 100 and 300 Jcm
 2, 1–5mgkg
 1 and 10–240min respectively, were varied and the response to PDT was analysed by
staging the macroscopic response and by the histological examination of the sections of the irradiated cheek pouch. A fast time decay
of the tissular response with drug dose of 1–5mgkg
 1 was observed for DLI ranging from 10 to 240min and for light doses of 100–
300Jcm
 2 delivered at a light dose rate of 150mWcm
 2. A significantly higher level of tissular response was observed for squamous
cell carcinoma compared to normal tissue. Nevertheless, the threshold level of the drug–light dose for a detectable response was not
significantly different in the tumoral vs normal tissue. The highest response at the shortest DLIs and the absence of measurable
response at DLI larger than 240min at light dose of 300Jcm
 2 and drug dose of 5mgkg
 1 reveals the predominantly vascular effect
of Tookad
s. This observation suggests that Tookad
s could be effective in PDT of vascularised lesions.
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Photodynamic therapy (PDT) is developing as a treatment for
cancer of the oesophagus (Radu et al, 2000), bronchi (Savary et al,
1997; Metz and Friedberg, 2001), bladder (Guillemin et al, 2001;
Jichlinski and Leisinger, 2001) as well as for other nononcological
applications such as the treatment of age-related macular
degeneration with the recent approval of the benzoporphyrin
derivative Visudyne
s and Verteporfin
s (Brown and Mellish,
2001). Photodynamic therapy is also a successful noninvasive
therapeutic modality for treating cutaneous neoplasm (Fritsch et al,
1998; Karrer et al, 2001). Current photosensitisers (PS) (Photo-
frin
s, Foscan
s and Metvix
s) accepted for the curative treatment
of oncological indications still present strong drawbacks, such as
prolonged skin (S) photosensitisation, scarring of healthy tissue,
interpatient fluctuations, and intralesion heterogeneity (Grosjean
et al, 1996; Webber et al, 1999). These drawbacks are due to the
difficulties in predicting the response to the drug dose and to the
lack of specificity for the targeted tissue Therefore, PDT is
currently restricted to a limited number of clinical indications. The
selectivity of a PS for neoplasm remains a main goal for new PSs. It
has been reported that PSs of the pheophorbide type are
accumulating in the reticuloendothelial system, the liver, the
pancreas and the lungs, with a higher retention in pancreatic
tumour cells (Aprahamian et al, 1993; Hajri et al, 1999).
Photodynamic therapy of glioma xenografts with Pd-bacterio-
pheophorbide have been reported to decrease the development of
metastasis in the rat (Schreiber et al, 2002). But frequently, no
comparisons of the tissue response after PDT are reported between
neoplasic vs healthy tissue under the same experimental condi-
tions.
Tookad
s is a palladium-metalated bacteriopheophorbide. It has
an absorption spectrum typical for the bacteriochlorin macrocycle
with a main absorption peak of the monomeric form in the near
infrared at a wavelength of 762nm. The presence of an absorption
band at this wavelength allows treatment with a longer wavelength
source, which results in a deeper penetration of the irradiation
light (Ritz et al, 2001). This feature permits the more efficient
treatment of solid tumours or pigmented tissues in particular if the
interstitial approach is used (Chen et al, 2002). This advantage has
been demonstrated by the deeper necrotic area obtained by a PS of
the bacteriochlorin type (meta-(tetrahydroxy phenyl) bacterio-
chlorin (mTHBPC), labsorption max¼740nm) compared with the
chlorin type (meta-(tetra-hydroxyphenyl) chlorin (mTHPC),
labsorption max¼652nm) (Rovers et al, 2000). Finally, in vitro
assays of bacteriochlorophyll derivatives demonstrate a higher
phototoxic effect than haematoporphyrin derivative (Scherz et al,
2000; Rosenbach-Belkin et al, 1998).
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sThese promising results with other bacteriochlorins triggered
the present study on an in vivo animal model. The hamster cheek
pouch model has been used for studies of the pharmacokinetics of
PSs such as mTHPC and benzoporphyrin derivative mono acid
ring A (BPD-MA) (Andrejevic-Blant et al, 2000). The measurement
of the phototoxic effect, of the pharmacodynamics, and the
threshold of response on real physiological systems is a decisive
factor for the development of future protocols for PDT and is
essential in the early phase of development of new PSs. One
problem inherent to PDT is the number of parameters that
influence the therapeutic outcome. As it is difficult to optimise
many parameters in a clinical context for each new PS, the use of
an animal model provides relevant preclinical data for the clinical
PDT trials. In order to optimise the therapeutic outcome of PDT,
three parameters (drug dose (mgkg
 1), drug injection–light
irradiation time interval (DLI) (min) and the light dose (Jcm
 2))
were varied in the Syrian golden hamster healthy cheek pouch
model and the resulting levels of response after treatment were
measured. The selectivity of Tookad
s against tumoral tissue was
studied in respect to the response after simultaneous treatment on
squamous cell carcinoma and on healthy mucosae in terms of drug
dose, light dose and DLI. This model has previously been used with
chemically induced squamous cell carcinomas and mimics well the
carcinogenesis both macroscopically and microscopically of the
human upper aerodigestive tract and oesophagus (Andrejevic-
Blant et al, 1997a, 2001; Kingsbury et al, 1997).
The PDT conditions for the study of selectivity on squamous cell
carcinoma were then chosen so that the resulting levels of response
on the healthy cheek pouch were limited to permit evaluation of
the response of the tumour.
MATERIALS AND METHODS
Animals
A total of 144 Syrian golden hamsters (male, average weight
135750g) were used for the photodynamic treatments on the
cheek pouch. Animals were housed at room temperature with a 12-
h light/dark cycle. Food and drinking water were given ad libitum.
The study of the light dose, drug–light intervals and drug dose was
made using four animals per condition. In total, 120 animals were
used for the normal tissue study and 24 animals for selectivity
toward induced squamous cell carcinoma study. The animals used
for the study of selectivity were submitted to chemical tumour
induction on the left cheek pouch. The induction of squamous cell
carcinoma was produced by a regular topical application (three
times per week) on the mucosae of the left cheek pouch during 10
weeks with a 0.5% wv
 1 oily 7,12 dimethylbenz(a)-anthracene
(DMBA, Sigma Chemical, Buchs, Switzerland) following a pre-
viously described protocol (Andrejevic et al, 1996, Blant et al,
1996). At 12–14 weeks after the first application, the induced
carcinoma were invasive, exophytic tumours with a diameter size
of 2–8mm. The right cheek pouch, which was not painted with
DMBA, served for control purposes. All the experiments have been
carried out with ethical committee approval and meet the
standards required by the UKCCCR guidelines (Workman et al,
1998).
Photodynamic treatments
Photosensitiser The WST09, (CA Reg. No. 274679-00-4) produced
under the name Tookad
s by Steba-Biotech (2585 GB The Hague,
The Netherlands), is a palladium-metalated bacteriopheophorbide.
The solution of Tookad
s was used directly as the stabilised
micellar solution in aqueous medium provided by Negma-Lerads
(Magny-Les-Hameaux, France) at 5mgml
 1 (Batch No. L565331,
Lot No. 010116). Solutions at 2 and 1mgml
 1 were obtained by
dilution in a formulation buffer at pH 7.4 (Negma-Lerads, Magny-
Les-Hameaux, France).
The Tookad
s solution was administered by intracardiac
injection at 5, 2 or 1mgkg
 1 of body weight. Depending on
animal weight, the injection volume was between 90 and 200ml.
The precise intracardiac positioning of the needle was performed
by carefully sucking some blood and monitoring the blood reflux
in the syringe. All the injections and PDT experiments were
performed under intraperitoneal anaesthesia (ketalar 150mgkg
 1
and xylesine 15mgkg
 1. The animals were killed 4 days after
PDT treatment and the cheek pouch excised for macrophotogra-
phy and histological preparation. All the experiments have been
carried out with the ethical committee approval and meet the
standards required by the UKCCCR guidelines (Workman et al,
1998).
Light source Irradiation at 762nm was performed with a tunable
4W diode Laser Ceralas PDT 763 (CeramOptec GmbH, Bonn,
Germany).
Light delivery Photodynamic therapy on the mucosae of the
hamster cheek pouch was carried out using a light distributor with
a 12mm diameter cylindrical radial diffuser, equipped with a
circular side window of 1cm
2, producing a homogeneous
irradiation onto the inner cheek pouch in direct contact with the
diffuser as described in former publications (Blant et al, 1996;
Andrejevic-Blant et al, 1997b). For the comparison of the normal
and tumoral tissue, a simultaneous irradiation of both cheek
pouches was achieved using a fibre splitter dividing the power in
two equivalent part (CeramOptec GmbH, Bonn, Germany) and two
light distributors. A light dose rate of 150mWcm
 2 was used for
all treatments. The cylindrical diffusers were calibrated using an
integration sphere by comparison with a frontal light diffuser (FD-
1, Medlight SA, Ecublens, Switzerland) delivering 150mW
measured with a power-meter (Spectra Physics Power-meter
407A, Mountain View, CA, USA).
The light doses used for PDT were 100, 200 and 300Jcm
 2 and
DLIs of 10, 30, 120 and 240min, defined as the duration between
the end of injection and the beginning of the irradiation, were
used.
Histological preparation
The treated cheek pouches were resected, photographed, and then
fixed in 5% buffered formalin (pH¼7.0). The fixed specimens
were paraffin embedded, sectioned in 5mm thick slices and stained
with haematoxylin and eosin for histological examination. For
each animal, the necrotic area was examined in serial sections to
evaluate the depth of the histological necrosis extending to the
different mucosal layers.
Evaluation of the photodynamic effect
The assessment of the necrosis was made 4 days after PDT
treatment. In order to evaluate the depth and extent of the PDT
treatment, we used a tissue damage scale graded from 0 to 4. The
scaling is based on the lateral extension of the macroscopic
necrosis, the formation of fibrin and the in-depth extension of the
necrosis to the different mucosal layers after histological
examination of the tissues sections, in a similar way to the
previous studies with different PSs (Andrejevic-Blant et al, 1997a,
1998, Rosenbach-Belkin et al, 1998; Zellweger et al, 2000).
Histologically, the tissue damage scale is related with the number
of layers of tissue that are necrosed as well as the lateral extension
of the necrosis. The grading of the response was expressed
following the tissue damage scale summarised in Table 1.
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sStatistical analysis
The contralateral irradiation of the normal cheek pouch allows a
comparison of the level of response in each animal. The
significance of the difference between tumour and normal tissue
response was tested using the Wilcoxon matched-pairs signed-
rank test. The tests were conducted using S-Plus software from
Insightful Corporation (Seattle, WA, USA).
RESULTS
Macroscopic and histological aspects of the tissue reaction
The model of the Syrian hamster cheek pouch allows PDT
treatment to be performed on a controlled surface with different
layers of tissue, which are representative of the human aero-
digestive tract. Following PDT treatment, an inflammatory
reaction with oedema and necrosis developed during the following
days. The analysis of the induced necrosis was made 4 days after
PDT. The treatment of tumours requires a knowledge of the levels
of response of the healthy tissue after the PDT in order to choose
the conditions that are not highly necrotic for healthy tissue.
Similar tissue damage scales were used in several studies of the
PDT effects of other PSs such as Foscan
s (Andrejevic-Blant et al,
1997a, 2000).
In order to exclude all thermal effects due to the irradiation at
762nm and any effect due to the formulation under irradiation,
two blank series of four animals each were carried out: (a)
irradiation at 762nm with a light dose of 300Jcm
 2 and a light
dose rate of 150mWcm
 2 without PS and without injection of the
formulation buffer; (b) irradiation at 762nm with a light dose of
300Jcm
 2 after injection of the formulation buffer without PS. In
both blank series, no induced responses were observed (level 0),
ensuring that all necrosis were effectively due to PDT treatment
with Tookad
s.
The response level, as defined in Table 1, is presented in the
form of a histogram as a function of the DLIs and drug doses (D)
in Figures 1, 2 and 3, respectively, for light doses (L) of 300, 200
and 100Jcm
 2. The typical standard deviation is 70.6 on the
tissue damage scale. The analysis of the response graphs (Figures
1–3) show that, for each drug dose, a sharp decrease in response
was observed for a certain DLI: for DLI4120min at D¼5mgkg
 1
and for DLI430min at D¼2mgkg
 1. This corresponds to a
threshold level of drug that is necessary to produce a measurable
response after PDT. The response is limited to DLIs shorter than
240min, indicating a fast clearance of Tookad
s from the
irradiated tissue and from the circulation.
The different tissue layers are stacking in the mucosae in the
following order from the irradiation side: epithelium (E), lamina
propria (LP), inner striated muscle (SMI), diffuse connective tissue
(CT), outer striated muscle (SMO), and skin (S). The histological
analysis of the tissue sections has shown that the inflammatory
response and necrosis appears unexpectedly at the level of the
vascularised diffuse CT containing fibroblast, fibres of collagen
and elastin between the SMI and SMO layer’s and only at higher
drug dose or higher light dose at the level of the inner epithelial
layer (E). When necrosis is observed in the CT, it refers to the
cellular content of this tissue, the inflammation being associated
with an invasion by neutrophils. All necroses from response level 1
and 2 occur, therefore, in the submucosal layer first. The epithelial
tissue of the mucosae, which is in direct contact with the light
diffuser was preserved at the level of response 1 and 2 and
presented no damage as shown in the histological section
(Figure 4). This observation can be explained by a lower
vascularisation of the epithelium layer, than the CT layer, and
Table 1 Tissue damage scale
Tissue damage scale Macroscopically Microscopically
0 Absence of observable reaction No tissue destruction
1 Erythema Partial destruction of diffuse connective tissue (CT)
2 Necrosis with diametero irradiation surface; no significant
appearance of fibrin
Destruction of diffuse CT, lamina propria (LP); oedema of the tissue;
beginning of the polymorphonuclear leucocyte invasion; partial loss of nuclei
and striation in striated muscle (SM)
3 Necrosis and fibrin with diameterEirradiation surface Destruction of the mucosae epithelium (E), CT, and both muscular layer
(SMI, SMO), strong polymorphonuclear invasion of these layers.
4 Necrosis and fibrin with diameter4irradiation surface Destruction of all layers resulting in transmural necrosis
For the tissue damage scales 1 and 2, the epithelium was preserved. In these cases, the diameter of the necrosis was assessed through the epithelium due to its translucent
properties.
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Figure 1 Response level of normal tissue after PDT at a light dose of
300Jcm
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Figure 2 Response level of normal tissue after PDT at a light dose of
200Jcm
 2.
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At response level 2, the histological sections often present vascular
occlusions and stases as well as the beginning of an invasion by the
polymorphonuclear cells. At a response level 3, the necrosis
reaches the epithelial tissue and all layers of muscle as well as the
CT. At level 4, the necrosis extends across all the tissues, reaching
the external epithelium (outside skin) corresponding to a
transmural necrosis. At both levels 3 and 4, the extensive necrosis
is associated with extensive cell death, disappearance of the muscle
microstructure, and strong invasion by polymorphonuclear cells,
as well as an oedema of all the tissue layers.
From these observations, a contrast of the necrosis for the
vascularised diffuse CT and SM was induced at response level’s 1
and 2 following PDT treatment.
Selectivity of the phototherapeutic effect of Tookad
s on
chemically induced squamous cell carcinoma vs normal
mucosae
The induced squamous cell carcinoma were treated when the
tumours began to be invasive and exophytic, with a size ranging
between 2 and 8mm in diameter. The contralateral irradiation of
the cheek pouch allows a direct comparison of the PDT treatment
between healthy tissue and tumoral tissue. In order to study the
selectivity of the effect of Tookad
s on tumoral and normal tissue,
the PDT treatment was conducted simultaneously on both cheek
pouches of the hamster, that is, at the same DLI. The contralateral
irradiation allows a direct comparison of the level of damage on
the tumour and on the healthy tissue. The conditions of PDT
treatment for the squamous cell carcinoma were chosen according
to the results obtained on the normal cheek pouch in order to
produce only limited damage to the normal tissue. Therefore, only
light doses of 100 and 200Jcm
 2 and drug doses of 5 and
2mgkg
 1 were chosen. The response levels for the PDT-treated
tumour and the contralateral healthy tissue are presented in
Figure 5 for all the conditions producing a detectable effect. A
response level X3, corresponding to the lowest tissue reaction
generating a destruction of the tumour, was observed in 11 out of
16 animals for the following conditions:
D¼5mgkg
 1, L¼100Jcm
 2, DLI¼30 and 10min,
D¼5mgkg
 1, L¼200Jcm
 2, DLI¼120min
D¼2mgkg
 1, L¼200Jcm
 2, DLI¼30 and 10min.
An example of the macroscopic response with necrosis of a
tumour is given in Figure 6 (D¼5mgkg
 1, L¼100Jcm
 2,
DLI¼30min), the contralateral cheek pouch shows a response
of level 2. An histological section of tumour and of its contralateral
mucosae are given in Figure 7 (D¼5mgkg
 1, L¼100Jcm
 2,
Figure 3 Response level of normal tissue after PDT at a light dose of
100Jcm
 2.
E
LP
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Figure 4 Histological section of the cheek pouch showing level 2
damage, with a necrosis of muscle and CT with polymorphonuclear
invasion (between the black lines). An inflammatory oedema with stases of
blood vessels indicated by arrows is present. The skin not visible in this
figure, is located below the striated muscle layer. E¼epithelium;
LP¼lamina propria; SMI¼striated muscle inner layer; CT¼connective
tissue; SMO¼striated muscle outer layer. The lower bar represents
200mm.
0
1
2
3
4
Animal number
Healthy tissue Tumoral tissue
R
e
s
p
o
n
s
e
 
l
e
v
e
l
DLI = 10 min DLI = 10 min DLI = 30 min DLI = 120 min DLI = 120 min
D = 5 mg kg−2 D = 2 mg kg−2 D = 5 mg kg−2 D = 2 mg kg−2 D = 5 mg kgJ cm−2
L = 200 J cm−2 L = 200 J cm−2 L = 200 J cm−2 L = 100 J cm−2 L = 200 J cm−2
12 34 56 789 1 0 1 1 1 2 1 3 1 4 1 5 1 6
Figure 5 Response level of the tumour and contralateral healthy tissue after PDT.
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accumulation of neutrophils, whereas the contralateral mucosae
only shows level 1 damage in the diffuse connective tissue with
minimal presence of neutrophils. It is observed that the scattering
of the responses was twice higher in the simultaneous contralateral
irradiation experiment than in the single irradiation on the healthy
tissue. The statistical analysis of the levels of response between the
matched data for tumoral and normal tissue (presented in Figure 5)
in all the hamsters with induced carcinoma shows a significant
difference following the Wilcoxon matched-pairs signed-rank test
(ar0.001).
In order to determine if a lower threshold level of response
could be observed in the tumoral tissue, two conditions of
irradiation were chosen just below the threshold response for
healthy tissue: L¼200Jcm
 2, D¼2mgkg
 1 and DLI of 120min,
and L¼200Jcm
 2, D¼1mgkg
 1 and DLI of 30min. In both
conditions, no significant response on either tumoral or healthy
tissue was observed. This reveals that the threshold of response for
the squamous cell carcinoma could not be detected at a
significantly lower level than on the healthy mucosae for
irradiation at 200Jcm
 2 within the resolution of our experimental
model.
DISCUSSION
In the present preclinical study, we measured the photodynamic
activity of Tookad
s in terms of the three critical parameters used
in clinical phototherapy: drug dose, light dose and drug–light
interval. In clinical applications, it is essential to adjust these
parameters to get a specific level of tumour response and to
improve the therapeutic results, while minimising the risk of
complications. The hamster cheek pouch allows controlled
dosimetry on a superposition of histologically different layers of
tissue, which permits the study of the level of necrosis following
PDT. The steep decay of the PDT response, in terms of the
injection–irradiation interval, is dependent on the drug dose and
the light dose. This on/off character in this animal model makes
the drug dose, the light dose and the DLI critical parameters. The
very fast decay of the response and the absence of response for DLI
of 240min at a light dose of 300Jcm
 2 and a drug dose of
5mgkg
 1 are characteristic of a predominantly vascular effect.
This fast decay is in contrast to the methyl ester of bacteriopheo-
phorbide a, which has a concentration in the tumour peaking at 8h
after injection (Ismail et al, 1998).
A contrast of the damage toward vascularised connective tissue
and striated muscle was observed, the Tookad
s inducing first an
effect at the lowest drug–light doses in the diffuse connective
tissue and in the striated muscle before acting on the epithelial
tissue as shown by the cell death beginning on the inside of the
mucosae. The vascularised diffuse connective tissue is essential to
nourish and maintain the tissular integrity of the whole mucosae.
Therefore, at a higher level of damage, this observation suggests
that the epithelia are necrosed essentially due to the early necrosis
of the submucosal layers. This result is in contrast to other PSs
such as mTHPC, which provide a contrast in favour of the
epithelial tissue at long DLI (450h). It should be noted that this
50-h DLI is much longer than those considered in the present
study (Andrejevic-Blant et al, 1997a, 2000).
The rapid elimination of Tookad
s is an advantage for several
clinical applications and reduces the side effects. Rapid blood
clearance was already observed for other PSs such as benzopor-
phyrin derivative (BPD-MA). Therefore, Tookad
s might be well-
suited to the treatment of lesions sensitive to the neoangiogenesis
or neovascularised tumour as well as already vascularised tumour
(Los and Voest, 2001). The treatment of atherosclerotic plaques
(Yamaguchi et al, 2001) with other vascular PSs has shown
promising results on animal models, as well as on chronic
inflammatory reaction in rheumatoid arthritis (Chowdhary et al,
1998; Trauner et al, 1998; Hendrich et al, 2000). These pathologies
are potential targets for PSs with a fast clearance such as Tookad
s.
Tookad
s can be activated at relatively longer wavelengths than
other PS, which permits deeper light penetration into the tissues.
In addition, this opens the possibility of Tookad
s being useful in
treating pigmented tissues, which have relatively smaller absorp-
tions at longer wavelengths (Zilberstein et al, 2001).
Figure 6 Resection of the cheek pouch 4 days after PDT at drug dose of
5mgkg
 1, light dose of 100Jcm
 2, DLI¼30min. Left: Tul tumour
irradiated with total necrosis level 4, Tu2 tumour not irradiated. Right:R ,
Reference irradiation on healthy tissue, level 2. The bar represents 10mm.
E
LP
SMI
CT
SMO
S
Tu
S
SMO
CT
SMI
E
B
A
Figure 7 Histological section of the cheek after PDT. Light dose
100Jcm
 2, drug dose 5mgkg
 1, DLI¼30min. (A) Tumour (Tu) with
oedema, necrosis of the E, LP, striated muscle inner (SMI) and outer (SMO)
layer, and CT (level 3). The tumour contains dead cells and is invaded by
neutrophils. (B) Contralateral normal cheek pouch (level 1) The bar
represents 400mm.
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carcinoma and mimics well the neoplasic development of the
human aerodigestive tract (Andrejevic et al, 1996). The matched
pair comparison of the tumoral vs healthy mucosae shows a
significantly higher level of damage to the tumour. Therefore, a
higher response of the necrotic damage toward the tumour vs the
normal tissue can be obtained. These results can be attributed to
the vascularisation of the induced tumour, which makes the
tumour particularly sensitive to destruction by the PS present in
the blood compartment However, no significant difference in the
threshold of response (level of damage X1) for the drug dose and
the light dose could be highlighted in the tumoral vs healthy tissue.
A tissular or a cellular accumulation of the PS in the neoplasic
tissue should reveal a lower threshold of response compared to the
normal tissue, ideally allowing the treatment of tumours without
affecting the surrounding healthy tissue. In order to lower the
threshold of response, an improved targeting of tumour tissue is
desirable.. This may be achieved by coupling Tookad
s to
molecules, which may achieve better selectivity in neoplasic tissue
(Folli et al, 1992).
Some critical remarks about the extension of the results
obtained in such animal models have to be kept in mind for
future clinical applications. The binding of the PS molecules to
plasma protein after injection can be different in human and in the
hamster. This is of importance as the distribution of the PS in the
different physiological, tissular and subcellular compartments
(MacDonald et al, 1999) is strongly dependent on the degree of
molecular microaggregation and on the injected formulation
of the PS.
In conclusion, Tookad
s presents the profile of a PS with
predominantly vascular effects under the conditions of our
experiment, with a fast decay of the PDT response in terms of
the drug–light interval. A higher level of response was observed
towards vascularized tumours vs normal tissue. Neovascularisation
of tissue is essential for the growth of a solid tumour. The concept
of a near-infrared absorbing PS with predominantly vascular
localisation is an interesting potential treatment strategy.
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